Stock Comparison

JAZZ vs UNH

Jazz Pharmaceuticals PLC vs UnitedHealth Group Inc

The Verdict

JAZZ takes this one.

Winner

JAZZ

Jazz Pharmaceuticals PLC

0.7

out of 10

Distressed

UNH

UnitedHealth Group Inc

0.3

out of 10

Distressed

Head-to-Head

$11.9B

Market Cap

$276.2B

-33.3

P/E Ratio

22.9

-8.3%

Profit Margin

2.7%

-8.8%

Return on Equity

12.5%

1.2

Debt-to-Equity

0.0

Moderate

Overall Risk

Moderate-High

0.7

DVR Score

0.3

The Deep Dive

JAZZ0.7/10

Jazz Pharmaceuticals remains a well-established biopharmaceutical company with strong execution on its neuroscience and oncology portfolio. The Q4 2025 earnings beat, 10% YoY revenue growth, and 16% YoY Xywav revenue growth demonstrate stable performance. The advancement of zanidatamab (HER2+ GEA) with breakthrough designation and potential H2 2026 approval provides a significant near-term catalys...

Full JAZZ Analysis

UNH0.3/10

UnitedHealth Group (UNH) remains a healthcare titan, but its sheer scale and the highly regulated nature of its operations fundamentally limit its 10x growth potential within 3-5 years. The recent Optum Health operating loss of $278M in 2025 (compared to $7.77B income in 2024) is a significant concern, eroding the growth narrative that Optum once provided. Furthermore, the proposed 0.09% Medicare ...

Full UNH Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.